More MASH competition on the way as Lilly touts positive data

6 June 2024

The race to secure market share for GLP-1 agonists continues to develop, with Eli Lilly (NYSE: LLY) revealing more promising results for its option, tirzepatide.

A dual GLP-1/GIP medication branded as Mounjaro for diabetes and Zepbound for obesity, the therapy is performing well in the SYNERGY-NASH trial, results show.

Lilly is running the trial to test tirzepatide as an option for metabolic dysfunction-associated steatohepatitis (MASH), a treatment area which has been shaken up by the recent launch of Madrigal Pharmaceuticals’ (Nasdaq: MDGL) Rezdiffra (resmetirom), the first drug to be approved for the condition.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK